825625-07-8

Usage

Molecular Weight

465.66 g/mol

Appearance

Clear liquid

Boiling Point

High boiling point (specific value not provided)

Volatility

Low volatility

Stability

Stable compound

Solubility

Not specified, but generally soluble in organic solvents

Derivative of

Ethylenediaminetetraacetic acid (EDTA)

Function

Chelating agent

Applications

a. Pharmaceutical industry
b. Chemical research
c. Industrial processes

Uses

a. Binding and removing metal ions from solutions
b. Preparation of radiopharmaceuticals
c. Stabilizer in chemical reactions
d. Complexing agent in the synthesis of new materials

Potential Medical Applications

a. Contrast agent in magnetic resonance imaging (MRI)
b. Treatment for heavy metal poisoning

Structure

Consists of a cyclic structure with four nitrogen atoms, four acetic acid groups, and three tert-butyl groups attached to the ethyl ester functional group.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 468743-81-9 1-[1-(ethoxycarbonyl)methyl]-1,4,7,10-tetraazacyclododecane 
• 105-36-2 ethyl bromoacetate 
• 294-90-6 1,4,7,10-tetraazacyclododecan 
• 122555-91-3 1,4,7-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane 

Downstream Products

• 137076-54-1 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-acetic acid 
• 170908-81-3 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccinimidyl ester) 
• 819869-77-7 tri-tert-butyl 2,2’,2”-(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
• 173308-18-4 tri-tert-butyl 2,2',2''-(10-(2-methoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
• 1618093-96-1 2,2',2''-(10-(2-((2-(4-(diphenylphosphino)benzamido)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid 

Relevant academic research and scientific papers

Lanthanide(III) complexes of DOTA-glycoconjugates: A potential new class of lectin-mediated medical imaging agents

The synthesis and characterization of a new class of DOTA (1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane) mono-amide-linked glycoconjugates (glucose, lactose and galactose) of different valencies (mono, di and tetra) and their SmIII, EuIII and GdIII complexes are reported. The 1HNMR spectrum of EuIII-DOTALac2 shows the predominance of a single structural isomer of square antiprismatic geometry of the DOTA chelating moiety and fast rotation about the amide bond connected to the targeting glycodendrimer. The in vitro relaxivity of the GdIII-glycoconjugates was studied by 1H nuclear magnetic relaxation dispersion (NMRD), yielding parameters close to those reported for other DOTA monoamides. The known recognition of sugars by lectins makes these glycoconjugates good candidates for medical imaging agents (MRI and gamma scintigraphy).

Comparison and systematic optimization of synthetic protocols for DOTA-hydrazide generation

DOTA-based organometallic complexes are extensively used in functional and molecular imaging studies, as well as in radioimmunotherapy. DOTA forms thermodynamically stable and kinetically inert complexes with various different diagnostic and therapeutic metals, such as gadolinium, gallium, yttrium and indium. Here, we have compared and systematically optimized the two most commonly used synthetic protocols for generating DOTA-hydrazide complexes, identifying conditions which reduce overall reaction time and increase overall yield.

Photoresponsive host-guest chemistry and relaxation time of fluorinated cyclodextrin and T1=T* 2 arylazopyrazole-functionalized DOTA metal complexes

Light-responsive modulation of the longitudinal (T1) and transversal T *2) relaxation times of a fluorinated cyclodextrin has been achieved by host-guest complexation with arylazopyrazole-modified metal complexes in aqueous solution. This supramolecular concept can potentially be applied to the development of contrast agents for19F magnetic resonance imaging (MRI).

NOVEL GADOLINIUM-BASED COMPOUND, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASE COMPRISING THE SAME, AND MRI CONTRAST COMPOSITION

The gadolinium-based compound 1 is represented by the following formula. Chemical Formula 1. In Chemical Formula 1, RosA is a moiety derived from rosmarinic acid. The compounds according to the invention are compositions for treating or preventing inflamm

COMPOUND HAVING NOVEL STRUCTURE, ANTI-INFLAMMATORY AGENT COMPRISING SAME, AND CYCLOOXYGENASE-2 INHIBITOR COMPRISING SAME

In the compound of the present invention and in an anti-inflammatory agent, a cyclooxygenase-2 inhibitor, a therapeutic agent for brain diseases, and an MRI contrast medium, which each comprise the same compound, the compound of the present invention has

DOTA-Branched Organic Frameworks as Giant and Potent Metal Chelators

Multinuclear complexes as metallo-agents for clinical use have caught extensive attention. In this paper, using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as both a functioning unit and a constructing junction, we build a series of DOTA-branched organic frameworks with multiple chelating holes by organizing DOTA layer by layer. These giant chelators are well characterized, which reveals their nanosized and soft structures. Further experiments demonstrate that they could efficiently hold abundant metal ions with much higher kinetic stabilities than the conventional small DOTA chelator. Their corresponding polynuclear complexes containing Gd3+, Tb3+, or both show superior imaging properties, excellent feasibility for peripheral modification, and unusual kinetic stability. This work can be easily extended to the fabrication of diverse homomultinuclear complexes and core/shell heteromultinuclear complexes with multifunctional properties. We expect that this new type of giant molecules and the ligand-branching strategy would open up a new avenue for the design and construction of next-generation polymetallic agents with high performance and stabilities for biomedical applications.

RADIODRUG FOR DIAGNOSTIC/THERAPEUTIC USE IN NUCLEAR MEDICINE AND RADIO-GUIDED MEDICINE

Radio-drug suitable for performing radio-guided surgery, imaging diagnostics, radio-metabolic therapy.

Polyfunctionalised Nanoparticles Bearing Robust Gadolinium Surface Units for High Relaxivity Performance in MRI

The first example of an octadentate gadolinium unit based on DO3A (hydration number q=1) with a dithiocarbamate tether has been designed and attached to the surface of gold nanoparticles (around 4.4 nm in diameter). In addition to the superior robustness

Novel heterobimetallic radiotheranostic: Preparation, activity, and biodistribution

A novel RuII(arene) theranostic complex is presented. It is based on a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid macrocycle bearing a triarylphosphine and can be tracked in vivo by using the γ emission of 153Sm atoms.

MRI visualization of melanoma cells by targeting overexpressed sialic acid with a GdIII-dota-en-pba imaging reporter

By design: The novel MRI reporter GdIII-dota-en-pba (see picture) selectively binds to sialic acid residues, which are overexpressed on tumors. This imaging reporter accumulates in a murine melanoma B16-F10 mice xenograft and from the MRI signal intensity it is possible to quantify the sialic acid concentration that is directly associated with tumor malignancy. Copyright